Stephen L. Sabba, serving as a director at Ligand Pharmaceuticals Inc. (NASDAQ: LGND), executed a notable transaction on June 16, 2026, involving the sale of 2,145 shares of the company's common stock. The total value of this sale reached $544,830, with each share transacting at a price of $254.00. This divestment occurred against a backdrop of significant price movement, as Ligand's stock has appreciated by 130% over the preceding year. Current trading levels hover near the 52-week high of $267.27, according to data from InvestingPro.
Despite the upward momentum, valuation analysis from the same platform indicates that the stock may be trading above its fair value. Ligand Pharmaceuticals currently holds a market capitalization of $5.27 billion and operates with a price-to-earnings (P/E) ratio of 35. The insider transaction was not an isolated event; it immediately followed the acquisition of an identical number of shares on the same day, a move facilitated by the exercise of non-qualified stock options.
Sabba acquired the 2,145 shares by exercising options originally granted in 2017. The initial grant consisted of 2,456 shares, which were later adjusted to 2,145 shares due to the separation of OmniAb Inc. from Ligand Pharmaceuticals. The exercise price for these options was set at $66.13 per share, resulting in a total acquisition value of $141,848. These options carry an expiration date of May 25, 2027. Following the sale, Sabba's direct holdings in Ligand Pharmaceuticals stand at 33,629 shares. This total includes a recent grant of 836 restricted shares, approved by the Board of Directors on June 5, 2026, which was previously disclosed in a Form 4 filing dated June 9, 2026.
Beyond insider activity, Ligand Pharmaceuticals reported its first-quarter 2026 earnings results, which fell short of market expectations. The company posted an adjusted earnings per share (EPS) of $1.63, missing the projected $1.84 by an 11.41% margin. Revenue also underperformed, coming in at $51.72 million against anticipated figures of $59.07 million, representing a 12.44% shortfall. Concurrently, the company announced an amendment to its merger agreement with XOMA Royalty Corporation. This amendment introduces XOMA Royalty Holdings Corporation as a party to the agreement. Under the revised structure, Flex Merger Sub, Inc., a wholly owned subsidiary of Ligand, will merge with HoldCo, a newly formed subsidiary of XOMA Royalty. Post-merger, HoldCo will remain a wholly owned subsidiary of Ligand, reflecting ongoing strategic adjustments within the organization.